- Home
- BCAB vs IKNA Comparison
BCAB vs IKNA Comparison
Compare BCAB & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- IKNA
- Stock Information
- Founded
- BCAB 2007
- IKNA 2016
- Country
- BCAB United States
- IKNA United States
- Employees
- BCAB N/A
- IKNA N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- BCAB Health Care
- IKNA Health Care
- Exchange
- BCAB Nasdaq
- IKNA Nasdaq
- Market Cap
- BCAB 96.2M
- IKNA 83.0M
- IPO Year
- BCAB 2020
- IKNA 2021
- Fundamental
- Price
- BCAB $2.08
- IKNA $1.68
- Analyst Decision
- BCAB Strong Buy
- IKNA Buy
- Analyst Count
- BCAB 2
- IKNA 2
- Target Price
- BCAB $6.00
- IKNA $3.00
- AVG Volume (30 Days)
- BCAB 1.6M
- IKNA 41.6K
- Earning Date
- BCAB 11-08-2024
- IKNA 11-07-2024
- Dividend Yield
- BCAB N/A
- IKNA N/A
- EPS Growth
- BCAB N/A
- IKNA N/A
- EPS
- BCAB N/A
- IKNA N/A
- Revenue
- BCAB N/A
- IKNA $1,844,000.00
- Revenue This Year
- BCAB N/A
- IKNA N/A
- Revenue Next Year
- BCAB N/A
- IKNA N/A
- P/E Ratio
- BCAB N/A
- IKNA N/A
- Revenue Growth
- BCAB N/A
- IKNA N/A
- 52 Week Low
- BCAB $1.14
- IKNA $1.02
- 52 Week High
- BCAB $4.02
- IKNA $4.63
- Technical
- Relative Strength Index (RSI)
- BCAB 55.80
- IKNA 51.57
- Support Level
- BCAB $1.87
- IKNA $1.68
- Resistance Level
- BCAB $2.13
- IKNA $1.78
- Average True Range (ATR)
- BCAB 0.12
- IKNA 0.04
- MACD
- BCAB 0.00
- IKNA 0.00
- Stochastic Oscillator
- BCAB 68.90
- IKNA 36.36
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.